MacroGenics, Inc. News Releases http://ir.macrogenics.com/ MacroGenics, Inc. News Releases en MacroGenics to Participate in Jefferies Healthcare Conference http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-jefferies-healthcare-conference Rockville, MD , May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will Thu, 30 May 2019 07:30:00 -0400 MacroGenics, Inc. News Releases 11666 MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-host-conference-call-and-webcast-review-margetuximab Rockville, MD , May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio Tue, 28 May 2019 16:30:00 -0400 MacroGenics, Inc. News Releases 11656 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-positive-results-phase-3-sophia-study Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) Oral abstract will be presented at American Society of Clinical Oncology ( ASCO ) Annual Meeting on June 4, 2019 at 9:45 a.m. Wed, 15 May 2019 17:07:00 -0400 MacroGenics, Inc. News Releases 11586 MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-2 Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, Wed, 01 May 2019 16:01:00 -0400 MacroGenics, Inc. News Releases 11561 MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-date-first-quarter-2019-financial-results ROCKVILLE, MD , April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its Wed, 24 Apr 2019 16:30:00 -0400 MacroGenics, Inc. News Releases 11551 MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019 http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-reports-presentation-data-aacr-annual-meeting-2019 ROCKVILLE, MD , April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of preclinical and Wed, 03 Apr 2019 16:30:00 -0400 MacroGenics, Inc. News Releases 11526 MacroGenics to Participate in Upcoming Investor Conferences http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-upcoming-investor-conferences-0 ROCKVILLE, MD , April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will Tue, 02 Apr 2019 17:00:00 -0400 MacroGenics, Inc. News Releases 11516 MacroGenics to Participate in Upcoming Investor Conferences http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-upcoming-investor-conferences ROCKVILLE, MD , March 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will Fri, 08 Mar 2019 17:30:00 -0500 MacroGenics, Inc. News Releases 11456 MacroGenics Provides Update on Corporate Progress and 2018 Financial Results http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2018 Margetuximab: Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019; Plans to initiate Phase 2/3 registration-directed, front-line gastric cancer study Enoblituzumab: Encouraging anti-PD-1 combo data supports Phase 2 study initiation in second half of 2019 PD-1 Tue, 26 Feb 2019 16:01:00 -0500 MacroGenics, Inc. News Releases 11431 MacroGenics Announces Participation in SVB Leerink Global Healthcare Conference http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-participation-svb-leerink-global ROCKVILLE, MD , Feb. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will Mon, 25 Feb 2019 17:00:00 -0500 MacroGenics, Inc. News Releases 11411